Literature DB >> 26474155

Brief Report: Association of Myositis Autoantibodies, Clinical Features, and Environmental Exposures at Illness Onset With Disease Course in Juvenile Myositis.

G Esther A Habers1, Adam M Huber2, Gulnara Mamyrova3, Ira N Targoff4, Terrance P O'Hanlon5, Sharon Adams6, Janardan P Pandey7, Chantal Boonacker1, Marco van Brussel1, Frederick W Miller5, Annet van Royen-Kerkhof1, Lisa G Rider5.   

Abstract

OBJECTIVE: To identify early factors associated with disease course in patients with juvenile idiopathic inflammatory myopathies (IIMs).
METHODS: Univariable and multivariable multinomial logistic regression analyses were performed in a large juvenile IIM registry (n = 365) and included demographic characteristics, early clinical features, serum muscle enzyme levels, myositis autoantibodies, environmental exposures, and immunogenetic polymorphisms.
RESULTS: Multivariable associations with chronic or polycyclic courses compared to a monocyclic course included myositis-specific autoantibodies (multinomial odds ratio [OR] 4.2 and 2.8, respectively), myositis-associated autoantibodies (multinomial OR 4.8 and 3.5), and a documented infection within 6 months of illness onset (multinomial OR 2.5 and 4.7). A higher overall clinical symptom score at diagnosis was associated with chronic or monocyclic courses compared to a polycyclic course. Furthermore, severe illness onset was associated with a chronic course compared to monocyclic or polycyclic courses (multinomial OR 2.1 and 2.6, respectively), while anti-p155/140 autoantibodies were associated with chronic or polycyclic courses compared to a monocyclic course (multinomial OR 3.9 and 2.3, respectively). Additional univariable associations of a chronic course compared to a monocyclic course included photosensitivity, V-sign or shawl sign rashes, and cuticular overgrowth (OR 2.2-3.2). The mean ultraviolet index and highest ultraviolet index in the month before diagnosis were associated with a chronic course compared to a polycyclic course in boys (OR 1.5 and 1.3), while residing in the Northwest was less frequently associated with a chronic course (OR 0.2).
CONCLUSION: Our findings indicate that myositis autoantibodies, in particular anti-p155/140, and a number of early clinical features and environmental exposures are associated with a chronic course in patients with juvenile IIM. These findings suggest that early factors, which are associated with poorer outcomes in juvenile IIM, can be identified.
© 2016, American College of Rheumatology.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26474155      PMCID: PMC4767657          DOI: 10.1002/art.39466

Source DB:  PubMed          Journal:  Arthritis Rheumatol        ISSN: 2326-5191            Impact factor:   10.995


  29 in total

Review 1.  Polymyositis and dermatomyositis (first of two parts).

Authors:  A Bohan; J B Peter
Journal:  N Engl J Med       Date:  1975-02-13       Impact factor: 91.245

2.  History of infection before the onset of juvenile dermatomyositis: results from the National Institute of Arthritis and Musculoskeletal and Skin Diseases Research Registry.

Authors:  Lauren M Pachman; Rebecca Lipton; Rosalind Ramsey-Goldman; Eli Shamiyeh; Kathy Abbott; Eduardo P Mendez; Alan Dyer; Deborah Mc Curdy; Larry Vogler; Ann Reed; Gail Cawkwell; Lawrence Zemel; Christy Sandborg; Rafael Rivas-Chacon; Christine Hom; Norman Ilowite; Abraham Gedalia; Jonathan Gitlin; Michael Borzy
Journal:  Arthritis Rheum       Date:  2005-04-15

3.  Brief report: ultraviolet radiation exposure is associated with clinical and autoantibody phenotypes in juvenile myositis.

Authors:  Mona Shah; Ira N Targoff; Madeline M Rice; Frederick W Miller; Lisa G Rider
Journal:  Arthritis Rheum       Date:  2013-07

4.  Immunogenetic risk and protective factors for juvenile dermatomyositis in Caucasians.

Authors:  Gulnara Mamyrova; Terrance P O'Hanlon; Jason B Monroe; Danielle Mercatante Carrick; James D Malley; Sharon Adams; Ann M Reed; Ejaz A Shamim; Laura James-Newton; Frederick W Miller; Lisa G Rider
Journal:  Arthritis Rheum       Date:  2006-12

5.  Long-term outcome and prognostic factors of juvenile dermatomyositis: a multinational, multicenter study of 490 patients.

Authors:  Angelo Ravelli; Lucia Trail; Cristina Ferrari; Nicolino Ruperto; Angela Pistorio; Clarissa Pilkington; Susan Maillard; Sheila K Oliveira; Flavio Sztajnbok; Ruben Cuttica; Matilde Beltramelli; Fabrizia Corona; Maria Martha Katsicas; Ricardo Russo; Virginia Ferriani; Ruben Burgos-Vargas; Silvia Magni-Manzoni; Eunice Solis-Valleoj; Marcia Bandeira; Francesco Zulian; Vicente Baca; Elisabetta Cortis; Fernanda Falcini; Maria Alessio; Maria Giannina Alpigiani; Valeria Gerloni; Claudia Saad-Magalhaes; Rosanna Podda; Clovis A Silva; Loredana Lepore; Enrico Felici; Federica Rossi; Elena Sala; Alberto Martini
Journal:  Arthritis Care Res (Hoboken)       Date:  2010-01-15       Impact factor: 4.794

6.  Cumulative organ damage and prognostic factors in juvenile dermatomyositis: a cross-sectional study median 16.8 years after symptom onset.

Authors:  Helga Sanner; Jan-Tore Gran; Ivar Sjaastad; Berit Flatø
Journal:  Rheumatology (Oxford)       Date:  2009-09-23       Impact factor: 7.580

7.  Immunoglobulin gene polymorphisms are susceptibility factors in clinical and autoantibody subgroups of the idiopathic inflammatory myopathies.

Authors:  Terrance P O'Hanlon; Lisa G Rider; Adam Schiffenbauer; Ira N Targoff; Karen Malley; Janardan P Pandey; Frederick W Miller
Journal:  Arthritis Rheum       Date:  2008-10

8.  Assessment of an infectious disease history preceding juvenile dermatomyositis symptom onset.

Authors:  C Manlhiot; L Liang; D Tran; A Bitnun; P N Tyrrell; B M Feldman
Journal:  Rheumatology (Oxford)       Date:  2008-02-27       Impact factor: 7.580

9.  Persistent association of nailfold capillaroscopy changes and skin involvement over thirty-six months with duration of untreated disease in patients with juvenile dermatomyositis.

Authors:  Stéphanie Christen-Zaech; Roopa Seshadri; Joyce Sundberg; Amy S Paller; Lauren M Pachman
Journal:  Arthritis Rheum       Date:  2008-02

10.  Is juvenile dermatomyositis a different disease in children up to three years of age at onset than in children above three years at onset? A retrospective review of 23 years of a single center's experience.

Authors:  Anjali Patwardhan; Robert Rennebohm; Igor Dvorchik; Charles H Spencer
Journal:  Pediatr Rheumatol Online J       Date:  2012-09-20       Impact factor: 3.054

View more
  19 in total

1.  Anti-NT5C1A autoantibodies are associated with more severe disease in patients with juvenile myositis.

Authors:  Richard M Yeker; Iago Pinal-Fernandez; Lisa G Rider; Andrew L Mammen; Takayuki Kishi; Katherine Pak; Ira N Targoff; Frederick W Miller
Journal:  Ann Rheum Dis       Date:  2018-01-23       Impact factor: 19.103

2.  Corticosteroid discontinuation, complete clinical response and remission in juvenile dermatomyositis.

Authors:  Takayuki Kishi; William Warren-Hicks; Nastaran Bayat; Ira N Targoff; Adam M Huber; Michael M Ward; Lisa G Rider
Journal:  Rheumatology (Oxford)       Date:  2021-05-14       Impact factor: 7.580

Review 3.  Advances in Juvenile Dermatomyositis: Myositis Specific Antibodies Aid in Understanding Disease Heterogeneity.

Authors:  Lauren M Pachman; Amer M Khojah
Journal:  J Pediatr       Date:  2018-04       Impact factor: 4.406

4.  Autoantibodies targeting TRIM72 compromise membrane repair and contribute to inflammatory myopathy.

Authors:  Kevin E McElhanon; Nicholas Young; Jeffrey Hampton; Brian J Paleo; Thomas A Kwiatkowski; Eric X Beck; Ana Capati; Kyle Jablonski; Travis Gurney; Miguel A Lopez Perez; Rohit Aggarwal; Chester V Oddis; Wael N Jarjour; Noah Weisleder
Journal:  J Clin Invest       Date:  2020-08-03       Impact factor: 14.808

Review 5.  Autoantibodies in myositis.

Authors:  Neil J McHugh; Sarah L Tansley
Journal:  Nat Rev Rheumatol       Date:  2018-04-20       Impact factor: 20.543

Review 6.  Advances Toward Precision Medicine in Juvenile Dermatomyositis.

Authors:  Jessica Neely; Susan Kim
Journal:  Curr Rheumatol Rep       Date:  2019-12-07       Impact factor: 4.592

7.  Long-term outcomes in Juvenile Myositis patients.

Authors:  Vladislav Tsaltskan; Annette Aldous; Sam Serafi; Anna Yakovleva; Heidi Sami; Gulnara Mamyrova; Ira N Targoff; Adam Schiffenbauer; Frederick W Miller; Samuel J Simmens; Rodolfo Curiel; Olcay Y Jones; Lisa G Rider
Journal:  Semin Arthritis Rheum       Date:  2019-06-28       Impact factor: 5.532

8.  Association of Anti-3-Hydroxy-3-Methylglutaryl-Coenzyme A Reductase Autoantibodies With DRB1*07:01 and Severe Myositis in Juvenile Myositis Patients.

Authors:  Takayuki Kishi; Lisa G Rider; Katherine Pak; Lilliana Barillas-Arias; Michael Henrickson; Paul L McCarthy; Bracha Shaham; Pamela F Weiss; Iren Horkayne-Szakaly; Ira N Targoff; Frederick W Miller; Andrew L Mammen
Journal:  Arthritis Care Res (Hoboken)       Date:  2017-07       Impact factor: 4.794

9.  Medications received by patients with juvenile dermatomyositis.

Authors:  Takayuki Kishi; Nastaran Bayat; Michael M Ward; Adam M Huber; Lan Wu; Gulnara Mamyrova; Ira N Targoff; William J Warren-Hicks; Frederick W Miller; Lisa G Rider
Journal:  Semin Arthritis Rheum       Date:  2018-03-28       Impact factor: 5.532

10.  Features distinguishing clinically amyopathic juvenile dermatomyositis from juvenile dermatomyositis.

Authors:  Gulnara Mamyrova; Takayuki Kishi; Ira N Targoff; Alison Ehrlich; Rodolfo V Curiel; Lisa G Rider
Journal:  Rheumatology (Oxford)       Date:  2018-11-01       Impact factor: 7.580

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.